Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Solid Biosciences Inc. is a clinical-stage life sciences company focused on developing genetic medicines for neuromuscular and cardiac diseases, with its primary emphasis on Duchenne muscular dystrophy (DMD). The company operates within the biotechnology and biopharmaceutical industries, specializing in gene therapy, gene editing, and precision genetic medicines. Its core value proposition is the development of potentially disease-modifying therapies for rare and severe genetic disorders with high unmet medical need.
The company’s primary revenue drivers are research and development activities supported by equity financing, collaborations, and, to a limited extent, grant funding, as it does not yet generate product sales revenue. Solid Biosciences is uniquely positioned through its integrated approach that combines gene transfer, gene editing, and targeted delivery technologies. Founded in 2013, the company has evolved from an early-stage gene therapy platform into a focused clinical-stage organization with multiple programs addressing DMD and related neuromuscular conditions.
Business Operations
Solid Biosciences conducts its operations primarily through a single operating segment focused on genetic medicine research and development. Its lead clinical program, IGNITE DMD, is based on the SGT-001 and next-generation SGT-003 microdystrophin gene therapy candidates, which use adeno-associated virus (AAV) vectors to deliver functional dystrophin genes to muscle tissue. The company also operates a gene editing platform known as Precision Genetic Medicines, which includes preclinical programs leveraging CRISPR-based technologies.
Operations are primarily U.S.-based, with research, development, and administrative functions centralized at its headquarters. Solid Biosciences controls proprietary AAV capsids, manufacturing know-how, and preclinical research assets, while relying on third-party contract manufacturing organizations for clinical-grade vector production. The company has historically entered into academic and research collaborations but does not currently report material joint ventures generating revenue.
Strategic Position & Investments
Strategically, Solid Biosciences is focused on advancing its lead DMD gene therapy programs through clinical development while expanding its pipeline into adjacent neuromuscular and cardiac indications. Growth initiatives center on improving vector design, increasing dystrophin expression, and enhancing safety profiles through next-generation constructs. The company has invested significantly in internal R&D capabilities and intellectual property to support long-term platform development.
Notable strategic investments include internal development of next-generation microdystrophin candidates and continued investment in gene editing research for muscle-targeted applications. Solid Biosciences does not maintain a broad portfolio of external equity investments but prioritizes disciplined capital allocation toward programs with clear clinical and regulatory pathways. Emerging areas of focus include cardiac manifestations of neuromuscular disease and improved systemic delivery technologies.
Geographic Footprint
Solid Biosciences is headquartered in the United States, with its principal offices and laboratory operations located in Massachusetts, a major global biotechnology hub. The company’s operational footprint is concentrated in North America, reflecting its focus on U.S.-based clinical trials, regulatory engagement, and research infrastructure.
Internationally, the company’s presence is primarily indirect, consisting of clinical trial sites outside the U.S. and relationships with global contract manufacturers and research partners. While Solid Biosciences does not maintain large overseas facilities, its clinical development activities and regulatory strategy are designed to support future market access in Europe and other major healthcare markets.
Leadership & Governance
Solid Biosciences is led by an executive team with experience in biotechnology, rare disease drug development, and capital markets. The leadership philosophy emphasizes scientific rigor, patient-centric development, and disciplined execution in high-risk therapeutic areas. Governance is overseen by a board of directors with expertise spanning biopharmaceutical development, finance, and regulatory affairs.
Key members of the leadership team include:
- Bo Cumbo – President and Chief Executive Officer
- Elizabeth L. Breen – Chief Financial Officer
- Dr. Kate A. Smith – Chief Scientific Officer
- Dr. Mark V. Petrone – Chief Medical Officer
- Dr. Gilmore O’Neill – Head of Technical Operations
The executive team’s strategic vision centers on advancing first- and best-in-class genetic medicines while maintaining compliance with regulatory standards and responsible governance practices.